Your company is already operating in Germany and you would now like to export worldwide?
Germany’s healthcare sector enjoyed a successful year with a resurgent biotech sector generating a quarter of new capital. New therapies are being developed for a range of autoimmune diseases and telemedicine service are on the rise.
The injectable Mounjaro that will be mass produced by Eli Lilly and Company in Germany has been cleared for use in helping people shed pounds.
In 2023, there was a notable resurgence in the financing available to Germany's biotechnology sector.
Germany is undertaking a “digital revolution” in healthcare and now has a strategy to make life easier for pharmaceutical companies.
Innovative start-ups are booming in Germany's attractive life sciences sector.
Japanese pharmaceuticals giant Takeda has put hundreds of millions of euros in recent years into its location in the southwestern German town of Singen to produce its anti-dengue-fever vaccine “Qdenga.”
The mood in German pharmaceuticals is bright, with companies looking to increase investment.
Germany's life sciences sector is proving attractive to start-up investors and international health companies alike.
Germany's medical technology sector secured more than EUR 2 billion in investment in 2021, with start-up companies and larger corporations alike developing great innovations.
Germany's life sciences sector was the top medical device FDI destination in 2019 and 2020. Companies including Bayer and BioNTech are also expanding their footprint in the country.
